Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Interomex BioPharmaceuticals
company
About
Interomex develops and commercializes technologies for functional analysis of genes and proteins.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $4M
- Industries
- Biopharma,Biotechnology,Medical
- Founded date
- Jan 1, 1999
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease.The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$4M
Interomex BioPharmaceuticals has raised a total of
$4M
in funding over 2 rounds. Their latest funding was raised on
Oct 5, 2001 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 5, 2001 | Series B | $4M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Interomex BioPharmaceuticals is funded by 1 investors.
T2C2 Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
T2C2 Capital
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
